Description: Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Home Page: www.sarepta.com
SRPT Technical Analysis
215 First Street
Cambridge,
MA
02142
United States
Phone:
617 274 4000
Officers
| Name | Title |
|---|---|
| Mr. Douglas S. Ingram Esq. | Pres, CEO & Director |
| Mr. Ian Michael Estepan | Exec. VP & CFO |
| Mr. William F. Ciambrone | Exec. VP of Technical Operations |
| Dr. Louise R. Rodino-Klapac Ph.D. | Exec. VP, Chief Scientific Officer and Head of R&D |
| Mr. Ryan E. Brown | Sr. VP, Gen. Counsel & Corp. Sec. |
| Bilal Arif | Sr. VP of Strategy and Operations |
| Mary Jenkins | Sr. Mang. of Investor Relations |
| Ms. Alison Nasisi | Chief People Officer & VP |
| Dr. Diane L. Berry | Sr. VP of Global Health Policy and Gov. & Patient Affairs |
| Mr. Dallan Murray | Sr. VP & Chief Customer Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 25.7374 |
| Price-to-Sales TTM: | 12.4903 |
| IPO Date: | 1997-06-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 840 |